Breaking barriers: Aptamers in ocular disease treatment
2024

Aptamers in Ocular Disease Treatment

Sample size: 14 Commentary Evidence: moderate

Author Information

Author(s): Wang Tao, Veedu Rakesh Naduvile

Primary Institution: The Kids Research Institute Australia, The University of Western Australia

Hypothesis

Can in vivo SELEX be used to develop RNA aptamers that effectively penetrate ocular barriers for treatment?

Conclusion

The study suggests that in vivo SELEX can lead to the development of aptamers that may provide a less invasive and more effective treatment for ocular diseases.

Supporting Evidence

  • Ocular diseases are projected to affect over 280 million people by 2040.
  • Current treatments often involve invasive procedures leading to poor patient compliance.
  • The study identified five different aptamer families based on nucleotide similarity.
  • Apt2 and Apt5 showed significant differences in biodistribution between ocular and control tissues.
  • Further research is needed to validate findings in human subjects.

Takeaway

Scientists are trying to create tiny molecules that can help treat eye diseases without needing painful injections. They found some that work better than others.

Methodology

The study used in vivo SELEX in rats to select RNA aptamers and analyzed them using next-generation sequencing.

Potential Biases

Potential biases in aptamer efficacy due to differences in incubation schemes or PCR processes.

Limitations

Further research is needed to assess the long-term safety and efficacy of these aptamers in humans.

Participant Demographics

Rats were used in the study.

Digital Object Identifier (DOI)

10.1016/j.omtn.2024.102399

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication